Publications by authors named "Sally Wade"

Claim this Profile
H
Health care resource utilization and costs associated with switching versus augmenting antidepressant monotherapy in second-line treatment of major depressive disorder.
Prakash S Masand, Nadia Nabulsi, François Laliberté, Guillaume Germain, Jacob Klimek, Sally W Wade

J Affect Disord· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term costs associated with outpatient use of axicabtagene ciloleucel in second-line and above relapsed/refractory large B-cell lymphoma based on the zuma-24 clinical trial.
Olalekan O Oluwole, Sally W Wade, Nathaniel J Smith, Tomas Spousta, Jenny Kim

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Disability Outcomes Among Patients Treated with Cariprazine vs Other Atypical Antipsychotics as Adjunctive Treatment for Major Depressive Disorder.
Prakash S Masand, Mousam Parikh, Jamie T Ta, Sally W Wade, Filmon Haile

Clinicoecon Outcomes Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of adjunctive cariprazine formulary restrictions in major depressive disorder.
Nadia Nabulsi, François Laliberté, Enrico Zanardo, Sean D MacKnight, Sophie Ma, Sally W Wade

Am J Manag Care· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Patient-Reported and Neurocognitive Outcomes in the Year After Axicabtagene Ciloleucel.
Aasha I Hoogland, Xiaoyin Li, Karnav Modi, Taylor Welniak, Yvelise Rodriguez, Sally W Wade

Transplant Cell Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns, health care resource utilization, and costs of chimeric antigen receptor T-cell vs standard therapy for relapsed/refractory mantle cell lymphoma in the United States.
Karl M Kilgore, Philip K Chan, Christie Teigland, Sally W Wade, Iman Mohammadi

J Manag Care Spec Pharm· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of cariprazine on body weight and blood pressure among adults with bipolar I disorder, schizophrenia, or major depressive disorder in a real-world setting.
Christoph U Correll, Andrew J Cutler, François Laliberté, Guillaume Germain, Sean D MacKnight, Sally W Wade

Ann Gen Psychiatry· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis.
James J Wu, Sally W Wade, Taha Itani, Jean-Gabriel Castaigne, Ioana Kloos

Leuk Lymphoma· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Retrospective Cross-Sectional Analysis of the Humanistic and Economic Burden of Bipolar I Disorder.
Larry Culpepper, Ashley Martin, Amanda Harrington, Sally W Wade, Mousam Parikh

Clin Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare resource utilization and costs associated with first versus subsequent use of cariprazine for bipolar I disorder.
Andrew J Cutler, François Laliberté, Guillaume Germain, Sean D MacKnight, Julien Boudreau, Sally W Wade

J Med Econ· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hospital healthcare resource utilization and costs for chimeric antigen T-cell therapy and autologous hematopoietic cell transplant in patients with large B-cell lymphoma in the United States.
Chendi Cui, Chaoling Feng, Ning Rosenthal, Sally W Wade, Laura Curry

Leuk Lymphoma· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies.
Olalekan O Oluwole, Sattva S Neelapu, Markqayne D Ray, Eve H Limbrick-Oldfield, Sally W Wade

Expert Rev Anticancer Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
Gilles Salles, Jenny M H Chen, Ina Zhang, Fabio Kerbauy, James J Wu, Sally W Wade

Adv Ther· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of formulary-related pharmacy claim rejections of cariprazine on health care utilization and treatment patterns among patients with bipolar I disorder.
François Laliberté, Enrico Zanardo, Sean D MacKnight, Ana Urosevic, Sally W Wade

J Manag Care Spec Pharm· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.
Georg Hess, Martin Dreyling, Lucie Oberic, Eva Gine, Pier Luigi Zinzani, Sally W Wade

Leuk Lymphoma· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-Adjusted Indirect Comparisons of Brexucabtagene Autoleucel with Alternative Standard Therapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients.
Bijal Shah, Jenny M H Chen, James J Wu, Chaoling Feng, Lang Zhou, Sally W Wade

Adv Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.
Georg Hess, Martin Dreyling, Lucie Oberic, Eva Gine, Pier Luigi Zinzani, Sally Wade

Br J Haematol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma.
Roxanna Seyedin, Julia T Snider, Krithika Rajagopalan, Sally W Wade, Usama Gergis

Future Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study.
Paola Ghione, M Lia Palomba, Hervé Ghesquieres, Sabela Bobillo, Anik R Patel, Sally W Wade

Haematologica· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
M Lia Palomba, Paola Ghione, Anik R Patel, Myrna Nahas, Sara Beygi, Sally W Wade

Expert Rev Anticancer Ther· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
Alice Kate Cummings Joyner, Julia Thornton Snider, Sally West Wade, Si-Tien Wang, Marric G Buessing

Adv Ther· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient preferences for treatment in relapsed/refractory diffuse large B-cell lymphoma: a discrete choice experiment.
Kelly Birch, Julia T Snider, Kevin Chiu, James Baumgardner, Sally W Wade

Future Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England.
Svenja Petersohn, Gilles Salles, Michael Wang, Jim Wu, Sally W Wade

J Med Econ· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma.
Julia Thornton Snider, Donna McMorrow, Xue Song, David Diakun, Sally W Wade

Clin Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States.
Claire L Simons, Daniel Malone, Michael Wang, Gregory A Maglinte, Tim Inocencio, Sally W Wade

J Med Econ· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis